The inherent heterogeneity of cancer - both inter-patient and intra-tumoral – remains a significant challenge in cancer modelling. With only 5% of cancer drugs successfully advancing to clinical trials, there is a critical need for more accurate and predictive models to guide therapeutic development.  

For the first time ever, the Tumour Models Summit Nordics united pharma, biotech, and research leaders across the thriving Nordic biotech ecosystem to tackle this challenge head-on. As the region’s only industry-led event of its kind, this summit provided attendees with a rare opportunity to connect with top experts in preclinical and translational research.

Attendees gained leading insights into the cutting-edge innovation in in vivo and in vitro tumour modelling, discovering strategies to de-risk their studies, whilst learning how to refine their drug development pipelines. Register your interest to be kept up to date on the 2026 meeting where you will be able to engage with decision-makers, explore ground breaking solutions, and accelerate the path from lab to patient in the rapidly evolving oncology landscape.